Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001564590-21-014024
Filing Date
2021-03-18
Accepted
2021-03-18 09:02:28
Documents
4
Effectiveness Date
2021-03-18

Document Format Files

Seq Description Document Type Size
1 S-8 agle-s8.htm S-8 135485
2 EX-5.1 agle-ex51_57.htm EX-5.1 15363
3 EX-23.1 agle-ex231_7.htm EX-23.1 2162
4 GRAPHIC gahpt1oicaw1000001.jpg GRAPHIC 19545
  Complete submission text file 0001564590-21-014024.txt   181100
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-254430 | Film No.: 21753218
SIC: 2834 Pharmaceutical Preparations